Treatment of children with newly diagnosed acute promyelocytic leukemia with arsenic trioxide: a single center experience (original) (raw)
- Original Manuscript
- Published: 09 September 2004
Therapy
Leukemia volume 18, pages 1587–1590 (2004) Cite this article
- 1342 Accesses
- 75 Citations
- 3 Altmetric
- Metrics details
Abstract
A total of 11 children (five males and six females) with hypergranular type of acute promyelocytic leukemia (APML) were treated with intravenous arsenic trioxide (As2O3) between December 1998 and October 2003. Eight cycles of As2O3 (0.15 mg/kg/day) were administered (induction, consolidation and six cycles of maintenance) over a period of 12 months. The median WBC count at diagnosis was 3400/mm3 (range: 800–9800). In all, 10 patients (91%) achieved hematological remission at a mean duration of 48 days (range: 41–60) with all 10 patients achieving molecular remission at a median duration of 81 days (range: 64–109). Toxicity was minimal with leukocytosis in six patients, ichthyosis and hyperpigmentation of skin in five and mild peripheral neuropathy in one patient. One patient who relapsed 6 months after completing therapy achieved a second hematological and molecular remission with As2O3. With a median follow-up of 30 months (range: 4–62), the overall (OS) survival is 91% with a relapse-free survival (RFS) of 81%. As2O3 achieves hematological and molecular remission in majority of newly diagnosed children with APML with minimal toxicity, but long-term follow-up is required to evaluate late effects of As2O3 and study the minimum dose and duration required for a sustained remission.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Figure 1

The alternative text for this image may have been generated using AI.
Figure 2

The alternative text for this image may have been generated using AI.
Figure 3

The alternative text for this image may have been generated using AI.
Similar content being viewed by others
References
- Gregory Jr J, Feusner J . Acute promyelocytic leukemia in children. Best Practice Res Clin Haematol 2003; 16: 483–494.
Article Google Scholar - Mann G, Reinhardt D, Ritter J, Hermann J, Schmitt K, Gadner H et al. Treatment with all-trans retinoic acid in acute promyelocytic leukemia reduces early deaths in children. Ann Haematol 2001; 80: 417–422.
Article CAS Google Scholar - Biondi A, Rovelli A, Cantu-Rajnodi A, Fenu S, Basso G, Luciano A et al. Acute promyelocytic leukemia in children: experience of the Italian Paediatric Hematology and Oncology Group (AIEOP). Leukemia 1994; 8: 1264–1268.
CAS PubMed Google Scholar - Bapna A, Nair R, Tapan KS, Nair CN, Kadam P, Gladstone B et al. All-trans-retinoic acid (ATRA): pediatric acute promyelocytic leukemia. Pediatr Hematol Oncol 1998; 15: 243–248.
Article CAS PubMed Google Scholar - Sanz MA, Martin G, Rayon C, Esteve J, Gonzalez M, Diaz-Mediavilla J et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood 1999; 94: 3015–3021.
CAS PubMed Google Scholar - Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 1997; 90: 1014–1021.
CAS PubMed Google Scholar - Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS et al. Studies on treatment of acute promyelocytic leukemia with arsenic tri-oxide: remission induction, follow-up and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999; 94: 3315–3324.
CAS PubMed Google Scholar - Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001; 19: 3852–3860.
Article CAS PubMed Google Scholar - Mathews V, Balasubramaniam P, Shaji RV, George B, Chandy M, Srivastava A . Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: a single center experience. Am J Hematol 2002; 70: 292–299.
Article CAS PubMed Google Scholar - Zhang P, Wang S, Hu L, Qiu F, Yang H, Xiao Y et al. Seven years summary report on the treatment of acute promyelocytic leukemia with arsenic trioxide – an analysis of 242 cases. Zhonghua Xue Ye Xue Za Zhi 2000; 21: 67–70.
PubMed Google Scholar - Hu X, Ma L, Hu N . Ailing No 1. in treating 62 cases of acute promyelocytic leukemia. Zhongguo Zhong Xi Yi Jie He Za Zhi 1999; 19: 473–476.
CAS PubMed Google Scholar - van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease: report of the BIOMED – 1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 1901–1928.
Article CAS PubMed Google Scholar
Author information
Authors and Affiliations
- Department of Haematology, Christian Medical College, Vellore, Tamil Nadu, India
B George, V Mathews, B Poonkuzhali, R V Shaji, A Srivastava & M Chandy
Authors
- B George
- V Mathews
- B Poonkuzhali
- R V Shaji
- A Srivastava
- M Chandy
Corresponding author
Correspondence toB George.
Rights and permissions
About this article
Cite this article
George, B., Mathews, V., Poonkuzhali, B. et al. Treatment of children with newly diagnosed acute promyelocytic leukemia with arsenic trioxide: a single center experience.Leukemia 18, 1587–1590 (2004). https://doi.org/10.1038/sj.leu.2403480
- Received: 18 March 2004
- Accepted: 09 June 2004
- Published: 09 September 2004
- Issue date: 01 October 2004
- DOI: https://doi.org/10.1038/sj.leu.2403480